IASLC 2016

PD-L1 Immunohistochemistry Assays Show Comparable Results

PD-L1 Immunohistochemistry Assays Show Comparable Results

By

PD-L1 Dako 28-8 and 22C3 assays and Ventana SP263 assay gave comparable results across dedicated platforms for PD-L1 presence.

Durvalumab Shows Durable Response in Metastatic NSCLC

Durvalumab Shows Durable Response in Metastatic NSCLC

By

Durvalumab led to durable responses in patients with heavily treated metastatic non-small cell lung cancer (NSCLC).

Tobacco Companies Seeking To Influence Policy Are Violating the Framework Convention on Tobacco Control

Tobacco Companies Seeking To Influence Policy Are Violating the Framework Convention on Tobacco Control

By

Tobacco industry representatives are continuing to meet with and are attempting to influence government officials in many countries.

Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC

Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLC

By

First-line ceritinib achieved statistically significant and clinically meaningful improvement in median progression-free survival (PFS).

Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC

Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLC

By

Addition of ganetespib to docetaxel does not improve efficacy for salvage therapy in patients with advanced stage non-small cell lung cancer (NSCLC).

Atezolizumab Improves Overall Survival Compared to Docetaxel in NSCLC

Atezolizumab Improves Overall Survival Compared to Docetaxel in NSCLC

By

Atezolizumab demonstrated improved overall survival (OS) compared to docetaxel for patients with unselected non-small cell lung cancer (NSCLC).

The Trans-Pacific Partnership Agreement (TPPA) May Pose a Threat to Public Health

The Trans-Pacific Partnership Agreement (TPPA) May Pose a Threat to Public Health

By

The Trans-Pacific Partnership Agreement (TPPA) contains provisions for tobacco products that threaten public health.

Pembrolizumab Improves QOL Compared to Chemotherapy in NSCLC

Pembrolizumab Improves QOL Compared to Chemotherapy in NSCLC

By

Pembrolizumab is associated with a clinically-meaningful improvement in health-related quality of life.

Icotinib Shows Progression-free Survival Benefit in NSCLC With Brain Metastases

Icotinib Shows Progression-free Survival Benefit in NSCLC With Brain Metastases

By

Icotinib demonstrated superior intracranial progression-free survival (iPFS), progression-free survival (PFS), and overall response rate (ORR).

Tumor, Node, and Metastasis Classification: 8th Edition Changes

Tumor, Node, and Metastasis Classification: 8th Edition Changes

By

The 8th Edition of the Tumor, Node and Metastasis (TNM) classification of lung cancer will help clinicians refine prognosis.

Osimertinib in EGFR T790M-positive Non-small Cell Lung Cancer

Osimertinib in EGFR T790M-positive Non-small Cell Lung Cancer

By

Osimertinib demonstrated better clinically-meaningful efficacy and a well-characterized safety profile compared to platinum pemetrexed.

International Cooperation Vital for Preventing Lung Cancer

International Cooperation Vital for Preventing Lung Cancer

By

Controlling tobacco use is vital to managing the threat it poses to public health, but doing so requires a multi pronged approach.

Oncoviruses and Epigenetic Factors May Contribute to Risk of Developing Lung Cancer

Oncoviruses and Epigenetic Factors May Contribute to Risk of Developing Lung Cancer

By

Although smoking is clearly a major risk factor, pathogenic viruses acquired from consumption of red meat may be a synergistic causative factor.

Multiple Genomic Mutations in Nearly 1% of Patients With NSCLC

Multiple Genomic Mutations in Nearly 1% of Patients With NSCLC

By

Double mutations do not significantly decrease overall survival (OS), but do alter progression-free survival (PFS) under first line treatment.

Switching From Docetaxel to Paclitaxel and Bevacizumab in NSCLC

Switching From Docetaxel to Paclitaxel and Bevacizumab in NSCLC

By

Allowing patients with non-squamous non-small cell lung cancer (NSCLC) to cross over demonstrated a progression-free survival (PFS) benefit.

Radiotherapy Doses Evaluated in NSCLC

Radiotherapy Doses Evaluated in NSCLC

By

A randomized phase 2 study found that 30 Grays (Gy) in 1 fraction is equivalent to 60 Gy in 3 fractions in terms of toxicity and survival.

Cabozantinib Safe and Effective in RET-rearranged Lung Cancer

Cabozantinib Safe and Effective in RET-rearranged Lung Cancer

By

Cabozantinib demonstrated safety and efficacy for treating patients with RET-rearranged lung cancer in an open-label, phase 2 trial.

Brigatinib Shows Promise in ALK-positive NSCLC With Brain Metastases

Brigatinib Shows Promise in ALK-positive NSCLC With Brain Metastases

By

Brigatinib has shown substantial clinical activity among patients with ALK-positive non-small cell lung cancer (NSCLC) who have brain metastases.

Concurrent Chemo-radiotherapy Viable for Elderly Patients With SCLC

Concurrent Chemo-radiotherapy Viable for Elderly Patients With SCLC

By

A high percentage of patients with limited-stage small cell lung cancer (SCLC) are elderly, but there is a lack of data concerning the efficacy and safety.

Researchers Find Modest Success in Tobacco Cessation Program

Researchers Find Modest Success in Tobacco Cessation Program

By

Researchers described "modest success" in a systematic multi-step clinical program to improve tobacco practices.

NSCLC Survival Associated With Institutional Differences in Quality of Care

NSCLC Survival Associated With Institutional Differences in Quality of Care

By

Institutional-level differences in the quality of care of patients with NSCLC are associated with differences in stage-stratified and overall survival (OS).

Next-generation Sequencing of ctDNA Could Identify Resistance Mutations in NSCLC

Next-generation Sequencing of ctDNA Could Identify Resistance Mutations in NSCLC

By

Next-generation sequencing (NGS) of circulating DNA (ctDNA) could be used to identify emergent resistance mutations.

Genetic Alterations in NSCLC May Indicate Improved Response to Veliparib

Genetic Alterations in NSCLC May Indicate Improved Response to Veliparib

By

Tumor genomes in tobacco users with non-small cell lung cancer (NSCLC) have genetic alterations that are associated with poor outcomes.

Alisertib Plus Paclitaxel Shows Promise for Patients With SCLC

Alisertib Plus Paclitaxel Shows Promise for Patients With SCLC

By

Alisertib showed antitumor activity in preclinical in vivo small cell lung cancer (SCLC) models.

Micrometastases in Lymph Node and 5-year Survival in NSCLC

Micrometastases in Lymph Node and 5-year Survival in NSCLC

By

Preoperative detection of micrometastases in the mediastinal lymph node (LN) during transcervical extended mediastinal lymphadenectomy (TEMLA).

New Biomarker Identified for Malignant Pleural Mesothelioma

New Biomarker Identified for Malignant Pleural Mesothelioma

By

Researchers discussed efforts to demonstrate that fibroblast growth factor 18 (FGF18) is overexpressed in malignant pleural mesothelioma (MPM) tissues and cell models.

New Prediction Model Could Guide Shared Decision Making in NSCLC

New Prediction Model Could Guide Shared Decision Making in NSCLC

By

A novel risk-prediction model can identify patients at an increased risk of mortality following surgical treatment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs